Phosphodiesterase type 5 inhibitors use and risk of colorectal cancer: a systematic review and meta-analysis.

Our findings suggest that continuous use of PDE5i was associated with a significantly reduced risk of CRC development. Future studies with a longitudinal design and adequate control of confounding factors are required to clarify whether a longer duration of PDE5i use alters the risk of CRC.